Fig. 6
From: Advances in molecular pathology and therapy of non-small cell lung cancer
Timeline of the research history and milestone events in targeted therapy for NSCLC. The annotation times in this illustration refer to the initial FDA or NMPA approval dates for each drug, whether under accelerated or regular approval. This timeline showcases the significant advancements in NSCLC treatments over the last five decades, featuring nine targetable biomarkers and over 30 drugs. These developments represent some of the most impressive progress across all cancer types. While this growth underscores the advancement of personalized medicine, the abundance of data also presents challenges in treatment selection, especially when our knowledge is limited. It is important to note that our data sources, the FDA and NMPA, do not include drugs approved in other regions. Progress in drug iterations has been particularly notable for EGFR and ALK TKIs, while advancements in other targets have been less prominent, highlighting the challenges in developing treatments for less common targets, which continue to represent unmet clinical needs
